Human ARSA (Arylsulfatase A) ELISA Kit (DEIA-FN127)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

serum, plasma, cell culture supernatants, tissue homogenate
Species Reactivity
Intended Use
For quantitative detection of Human ARSA (Arylsulfatase A) in serum, plasma, tissue homogenates and other biological fluids.
Contents of Kit
1. 96-well strip plate (Dismountable), 1 plate
2. Lyophilized Standard, 2 vials
3. Sample/Standard dilution buffer, 20 mL
4. Biotin-detection antibody (Concentrated), 120 uL
5. Antibody dilution buffer, 10 mL
6. HRP-Streptavidin Conjugate(SABC), 120 uL
7. SABC dilution buffer, 10 mL
8. TMB substrate, 10 mL
9. Stop solution, 10 mL
10. Wash buffer (25X), 30 mL
11. Plate Sealer, 5 pieces
12. Product Manual, 1 copy
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Intra-Assay: CV<8%
Inter-Assay: CV<10%
Detection Range
0.156-10 ng/mL
0.094 ng/mL
Standard Curve


Have you cited DEIA-FN127 in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate


Authors: Colle, Marie-Anne; Piguet, Francoise; Bertrand, Lise; Raoul, Sylvie; Bieche, Ivan; Dubreil, Laurence; Sloothaak, Didi; Bouquet, Celine; Moullier, Philippe; Aubourg, Patrick; Cherel, Yan; Cartier, Nathalie; Sevin, Caroline

Metachromatic leukodystrophy (MLD) is a lethal neurodegenerative disease caused by a deficiency in the lysosomal arylsulfatase A (ARSA) enzyme leading to the accumulation of sulfatides in glial and neuronal cells. We previously demonstrated in ARSA-deficient mice that intracerebral injection of a serotype 5 adeno-associated vector (AAV) encoding human ARSA corrects the biochemical, neuropathological and behavioral abnormalities. However, before considering a potential clinical application, scaling-up issues should be addressed in large animals. Therefore, we performed intracerebral injection of the same AAV vector (total dose of 3.8 x 10(11) or 1.9 x 10(12) vector genome, three sites of injection in the right hemisphere, two deposits per site of injection) into three selected areas of the centrum semiovale white matter, or in the deep gray matter nuclei (caudate nucleus, putamen, thalamus) of six non-human primates to evaluate vector distribution, as well as expression and activity of human ARSA. The procedure was perfectly tolerated, without any adverse effect or change in neurobehavioral examination. AAV vector was detected in a brain volume of 12-15 cm(3) that corresponded to 37-46% of the injected hemisphere. ARSA enzyme was expressed in multiple interconnected brain areas over a distance of 22-33 mm. ARSA activity was increased by 12-38% in a brain volume that corresponded to 50-65% of injected hemisphere. These data provide substantial evidence for potential benefits of brain gene therapy in patients with MLD.



Authors: Peeters, H.; Vermeesch, J.; Fryns, J. P.

A cryptic duplication 22q13.31 to qter leads to a distinct phenotype with mental retardation, microcephaly and mild facial dysmorphism: We present a girl with a terminal 22q duplication due to all unbalanced chromosomal translocation: 46, XX, der(22)(qter -> q13.31 :: p11 -> qter). She presented with mild to moderate mental retardation. autism spectrum disorder, microcephaly and mild dysmorphic facial features. Because of nasal speech and mental retardation. FISH analysis for the DiGeorge/VCFS region was performed. In this analysis, an extra signal for the control probe LSI ARSA (22q13) on the short arm of one of the chromosomes 22 revealed the terminal duplication 22qter. The duplication was confirmed by means of IMb array-CGH and Further delineated as a 5.5 Mb region: 46, XX, dup(22)(q13.31qter)(CTA-268H5 -> CTB-99K24)x3. Important phenotypic variability has been described among patients with terminal 22q duplications. However, by considering the present patient and a careful selection of literature reports describing pure trisomy 22qter and comparably small duplicated regions 22q13.3 to qter, we find evidence tor a consistent clinical presentation: mild to moderate mental retardation, microcephaly and similar mild dysmorphic Features. Furthermore we conclude that small terminal duplications of chromosome 22q may be more common than generally assumed but may remain undetected by high resolution karyotyping. The application of array-CGH in patients with mental retardation and only very mild dysmorphism may allow to detect small 22qter duplications more frequently.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket